Revised MRPs of 1,364 Anti-Cancer Formulations Come into Effect from Today

1. At a Glance

• NPPA capped the trade margin on 137 non-scheduled anti-cancer drugs at 30% of MRP, using its special power under Para 19, DPCO 2013. Revised MRPs took effect on 9 November 2026 [1][2].
• As on 8 November 2026, 85 companies had reported revised MRPs for 1,364 formulations covering 121 drugs. Expected consumer savings are ₹3,540.38 crore a year [1].
• It scales up the 2019 pilot of 42 drugs, which PIB described as a proof of concept [3].
• UPSC value: it links health affordability, drug-price regulation, inter-ministerial division of work and consumer-driven enforcement.

2. Why in the News

• 17 Oct 2026: Gazette notification capped trade margins on 137 anti-cancer drugs [2].
• 28 Oct 2026: NPPA released revised MRPs for an initial 543 brands, with the list to be updated continually [6].
• 8 Nov 2026: Reported position reached 1,364 formulations, 121 drugs and 85 companies. 679 brands reported cuts above 50%, and the highest cut was 96.45% [1].
• 9 Nov 2026: Revised MRPs came into force [1][2].

3. Background & Evolution

• Pre-2013: NPPA fixed prices under the DPCO 1995 formula [13].
• DPCO 2013: The current framework for regulating drug prices in India [10].
• 26 Feb 2019: NPPA invoked extraordinary powers in public interest (Para 19) to bring 42 non-scheduled anti-cancer drugs under Trade Margin Rationalisation (TMR) [4].
• 2019 outcome:
• Trade margin was capped at up to 30% of MRP, and MRPs of 526 brands fell by up to 90% [3].
• An earlier 2019 release reported MRPs of 390 non-scheduled anti-cancer medicines reduced by up to 87% [5].

• Later estimates put savings at about ₹984 crore a year, with about 500 brands reduced by an average of about 50% [11].

• Union Budget 2024-25: Customs duty was removed on three additional cancer medicines [12].

• 2026: TMR expanded to 137 drugs on an Expert Committee's recommendation [1][2].

4. Core Static Facts

Key distinctions

• Scheduled drugs: NLEM medicines are placed in the First Schedule of DPCO 2013, and NPPA fixes their ceiling prices [9][10].
• This action: It covers non-scheduled drugs through a margin cap, not a formula-based ceiling price [2].
• Trade margin cap vs MRP: The cap is the tool and the revised MRP is the outcome [1].

5. Multi-Dimensional Analysis

Economic

• Savings of ₹3,540.38 crore are about 3.6 times the ₹984 crore estimated for the 42-drug pilot [1][11]. The two are separate estimates, so the ratio is only indicative.
• Cuts of up to 96.45% suggest some products carried very wide margins [1]. This is an inference, not an official finding.
• Analysis: A margin cap targets distribution markups and leaves the drug unchanged, but it may squeeze trade incentives to stock low-priced brands.

Social

• A 2019 PIB release said cancer had the highest out-of-pocket spending of any disease in 2014 [4].
• Studies it cited suggest about 60% of households borrow and about 32% rely on friends and relatives for cancer hospitalisation [4].
• A Tata Memorial–ACTREC study found a 6-month course of some modern drugs can cost more than several years of income in India [8].

Legal / Regulatory

• Para 19 allows intervention beyond the scheduled list, in public interest [4].
• Analysis: Repeated use of an extraordinary power for a whole therapeutic class raises the question of whether TMR needs a standing statutory framework.

Administrative / Federal

• The process crosses ministries: Health advises and NPPA, under Chemicals and Fertilizers, implements [1].
• Enforcement relies on State Drug Controllers, which makes state capacity decisive [2].
• Direct hospital supply is explicitly covered, closing an obvious leakage route [2].

Ethical / Governance

• Public verification and grievance channels shift part of monitoring to consumers [1].
• Analysis: Patients in acute treatment, often buying through hospital pharmacies, are poorly placed to act as enforcers.

Scientific / Technological

• Coverage extends to high-cost modern therapies such as immunotherapy and biologic-type products [2].
• Funds for one pembrolizumab patient in India could treat 18–22 patients on lower-cost targeted therapies, so price cuts alone do not settle allocation [8].

6. Recent Developments (last 12-18 months)

• Mar 2026: Tata Memorial–ACTREC study on unaffordability of modern head and neck cancer drugs [8].
• Oct 2026: PIB release on expanded cancer price controls projected savings of ₹2,500 crore a year [7].
• 17 Oct 2026: Gazette notification on 137 drugs [2].
• 28 Oct 2026: First revised list of 543 brands [6].
• 8 Nov 2026: Reported coverage of 1,364 formulations, with 679 brands cut by more than 50% [1].
• 9 Nov 2026: Revised MRPs effective [1].

7. Prelims Hooks (high-density factual bullets)

• NPPA functions under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers [1].
• The Expert Committee was constituted by DGHS, Ministry of Health & Family Welfare [1].
• The 2026 margin cap was imposed under Para 19, DPCO 2013 [2].
• The trade margin cap is 30% of MRP [2].
• The cap covers 137 non-scheduled anti-cancer drugs [2].
• Revised MRPs took effect on 9 November 2026 [1].
• Manufacturers had to report revised prices within 7 days of Gazette publication [2].
• 1,364 formulations of 121 drugs were reported by 85 companies as on 8 November 2026 [1].
• Highest reported MRP reduction: 96.45% [1].
• Expected annual consumer savings: ₹3,540.38 crore [1].
• Pharma Sahi Daam is NPPA's app for checking medicine prices [1].
• Pharma Jan Samadhan is NPPA's portal for overcharging complaints [1].
• The first anti-cancer TMR, in February 2019, covered 42 drugs [4].
• NLEM medicines are incorporated in the First Schedule of DPCO 2013 [9][10].

8. The Cap Cuts the Trader's Share, Not the Company's Price

• The cap controls only one part of the price
• A trade margin is the share of the price kept by wholesalers and retailers.
• Example (not official data): at a 30% cap, if a company sells a drug at ₹70,000, the MRP (maximum retail price) can still be ₹1 lakh.

• So a drug with a very high company price stays very expensive after the cap.

• For new cancer drugs, the company's price is often the main problem

• WHO's 2018 report found that research and production costs may have little link to cancer drug prices [21].
• Companies often set prices by how much a buyer is willing to pay [21].

• A margin cap does not touch this decision.

• The same drug can cost very different amounts in different countries

• For pembrolizumab, a WHO document found prices from $12.23 to $60.98 per mg of API (the active ingredient), about a five-fold gap [24].
• It expects biosimilars (close, cheaper copies of biological drugs) in 3 to 5 years, which could lower prices sharply [24].

• Competition may therefore cut prices of the costliest drugs in ways a margin cap cannot.

• The Department of Pharmaceuticals and the Health Ministry should add a second tool for the costliest drugs

• WHO's guideline asks countries to use several pricing policies together, and not rely on one [22].
• Its list includes tendering (buyers ask companies to bid for a large order) and price transparency [22].
• Tendering pushes down the company's own price, which is the part this cap leaves alone.

9. How to Read the ₹3,540 Crore Savings Figure

• It is an estimate, and it moved quickly
• In October 2026, a PIB release projected savings of ₹2,500 crore a year [7].
• By 8 November, the figure was ₹3,540.38 crore, over ₹1,000 crore higher [1].

• Reports had also covered only 121 of the 137 drugs by then, so the final picture is not yet known [1][2].

• A lower MRP saves money only if the buyer was paying the old MRP

• A patient who already got a large discount saves less than the headline suggests.
• Where a scheme pays the bill, the saving goes first to the scheme and not to the patient.

• This is reasoning, not an official finding. The sources used here do not explain how the figure was calculated.

• A big percentage cut does not mean a big total saving

• The highest cut of 96.45% [1] means a ₹100 MRP fell to about ₹3.55. The old price was about 28 times the new one.

• This shows how high that one MRP was. It does not show how many patients bought that brand.

• Use the figure carefully in an answer

• Write 'expected savings of ₹3,540.38 crore a year' [1], not 'patients have saved'.

10. A Temporary Power Doing a Permanent Job

• Parliament's committees have now named this weakness directly
• A parliamentary committee noted that DPCO 2013 (the Drugs Prices Control Order) permits trade margin capping only for a limited period [16].
• It recommended amending DPCO to allow trade margin rationalisation and to regulate non-scheduled drugs (medicines outside the government's essential list) [16].

• In August 2026, the Standing Committee on Chemicals and Fertilisers (Report No. 33) again flagged the lack of a permanent trade margin framework [15].

• Without a standing rule, protection arrives only when a new order is issued

• The first cancer order came in 2019 and the wider one in 2026 [4][2].
• A cancer drug left out of the 2019 list had no margin cap for those seven years.

• Non-scheduled drugs can raise prices by up to 10% a year [17]. At that rate, a price nearly doubles in seven years.

• Check what happens when the period ends

• If the cap is time-limited and is not renewed, margins can widen again.

• The sources used here do not state how long the 2026 cap lasts, so read the Gazette before writing a date.

• The Department of Pharmaceuticals should write trade margin rules into DPCO itself

• The rule should say when a drug class enters the cap, for how long, and how it is reviewed. The committee's recommendation supports this [15][16].
• The rule should also fix the gaps Report No. 33 found in how scheduled and non-scheduled medicines are classified [15].

11. Why Catching an Overcharger Is Easier Than Getting the Money Back

• Recovery can get stuck in court for years
• When NPPA finds overcharging, it issues a demand notice, an order to repay the excess with interest [19].
• Companies can challenge this in court. In 2011, ₹1,930.41 crore of ₹2,328.53 crore in demand notices was under litigation, about 83% [18].
• In August 2026, the Standing Committee still reported large unrecovered amounts stuck in litigation [15].

• So a company may gain more by delaying than it risks by overcharging.

• Even when money is recovered, the patient may not see it

• A demand notice recovers the excess for the government, and the sources used here describe no route that refunds an individual patient.

• This matters most in cancer care, where the family may already have borrowed to pay [4].

• NPPA cannot show which state is failing

• Enforcement of this order rests on State Drug Controllers [2].
• But NPPA does not keep a state-wise record of overcharging by companies [19].

• Without that record, nobody can compare states or see where checks are weak.

• A low complaint count proves little

• State Price Monitoring and Resource Units and State Drug Controllers refer cases to NPPA [20].

• NPPA told Parliament it received no complaint about loose medicines being sold above per-unit MRP [20]. That shows only what was reported, not what happens in shops.

• NPPA should publish overcharging data by state

• The data should cover cases, amounts and recoveries.
• Report No. 33 has already pointed to incomplete data for price monitoring [15].

12. Could a Percentage Cap Push Cheaper Brands Off the Shelf?

• The strongest objection
• A cap set as a percentage pays the trader more on a costly brand.
• Example (not official data): at 30%, a seller can earn up to ₹3,000 on a ₹10,000 brand but only ₹300 on a ₹1,000 brand.
• So a trader may prefer to stock the costlier brand, or stop stocking cheap ones.

• A WHO South-East Asia review found evidence of unintended, harmful effects from several mark-up policies [23]. A mark-up is the amount added to a price at each step of the supply chain.

• What is right about it

• The incentive is real, because it follows directly from how a percentage works.

• The review warns that a price rule can backfire [23], so a fall in MRP alone does not prove success.

• Where it falls short

• The WHO review covers mark-up policies in the region in general, not India's cancer margin cap.
• The sources used here contain no study showing that the 2019 cancer drugs disappeared from shelves.
• Hospitals are also bound to the revised price on direct supply [2], which limits one way of avoiding the cap.

• So the risk is possible but unproven. An honest answer should say both.

• NPPA should track availability, not only price

• It should publish stock data for the 137 capped drugs from before and after 9 November 2026.
• This would settle the question with evidence, and would also help fix the data gap noted by the Standing Committee [15].

13. The Cap Reaches the Bills That Insurance Leaves Out

• This is the strongest argument in favour of the order
• PM-JAY (the government's health insurance scheme for poorer families) covers only inpatient care, meaning treatment after hospital admission [25].
• The Health Committee called this inadequate, because out-of-pocket spending (money patients pay themselves) is mostly on outpatient care and medicines [25].

• A lower MRP helps in the part of the bill that insurance does not pay.

• But cover and price cuts do not add up to full protection

• PM-JAY gives ₹5 lakh per family per year and defines 435 cancer procedures [26].
• A six-month course of some modern drugs can cost more than several years of income [8].

• Even a large cut may leave such a drug out of reach for a poor family.

• Cheap outlets are few

• AMRIT pharmacies offered 289 cancer medicines through 217 outlets as of June 2025 [27].

• For a patient far from these outlets, the MRP on the pack remains the price that matters.

• The Health Ministry should act on the committee's concern

• It should examine covering outpatient cancer medicines under PM-JAY, since the committee has identified that gap [25].
• Price control lowers the bill. Only insurance or public supply decides who pays what remains.

14. Anchors for Answers

• Data: ₹1,930.41 crore of ₹2,328.53 crore in NPPA demand notices was under litigation in 2011, about 83% [18]
• Data: Pembrolizumab costs from $12.23 to $60.98 per mg of active ingredient across countries [24]
• Data: PM-JAY gives ₹5 lakh per family per year, with 435 defined cancer procedures [26]
• Report/Committee: Standing Committee on Chemicals and Fertilisers, Report No. 33, August 2026 — no permanent trade margin framework, unrecovered overcharging dues, incomplete price data [15]
• Report/Committee: Parliamentary committee report on price rise of medicines — amend DPCO 2013 to allow trade margin rationalisation [16]
• Report/Committee: Standing Committee on Health and Family Welfare, 175th–177th Reports — PM-JAY's inpatient-only cover is inadequate [25]
• Report/Committee: WHO technical report on pricing of cancer medicines, 2018, under World Health Assembly Resolution 70.12 [21]
• Law/Case: Para 19, DPCO 2013 — power used for the cap [2]; non-scheduled drugs are limited to a 10% annual price rise [17]
• Comparison: WHO South-East Asia review — India is one of five countries in the region that set a ceiling on retail prices, and the review warns that several mark-up policies had harmful side effects [23]
• Comparison: WHO pricing guideline — use several policies together, including tendering and price transparency, to keep generic and biosimilar prices low [22]
• Scheme: AMRIT pharmacies — 289 cancer medicines through 217 outlets as of June 2025 [27]
• Scheme: PM-JAY — covers inpatient cancer care but leaves outpatient medicine costs to the patient [25][26]

15. Mains Relevance

• GS-II: Issues relating to development and management of social sector/services relating to Health; government policies and interventions.
• GS-III: Inclusive growth; effects of regulation on the pharmaceutical sector.
• Question stems: 1. "Trade margin rationalisation offers a targeted route to affordable medicines without direct price fixing." Critically examine with reference to anti-cancer drugs in India. 2. Discuss the adequacy of India's drug-price regulatory framework in reducing out-of-pocket expenditure on catastrophic illnesses. 3. Consumer-driven enforcement can supplement but not replace regulatory capacity. Examine in the context of medicine pricing in India.

16. Related Topics to Study Next

• DPCO 2013 and scheduled vs non-scheduled drugs: the legal core of this topic.
• National List of Essential Medicines: determines which drugs enter the First Schedule.
• Out-of-pocket health expenditure: the affordability problem the cap addresses.
• Trade margins on medical devices: the same policy question in an adjacent sector [14].
• AMRIT pharmacies: sell cancer drugs at substantial discounts to MRP [12].
• Customs duty exemptions on cancer medicines: a parallel, tax-side affordability lever [12].
• PLI for pharmaceuticals and medical devices: the supply-side counterpart to price control.
• Compulsory licensing and patents on cancer drugs: an alternative route to access for high-cost therapies.

17. NCERT Concepts to Revise

• Trade margin rationalisation (Economy): The core policy: capping the trader's margin at 30% of MRP on 137 anti-cancer drugs.
• Drugs (Prices Control) Order, 2013 (Economy): The legal framework, and its Para 19 public-interest power, that NPPA used for this cap.
• National Pharmaceutical Pricing Authority (Polity): The regulator that issued the cap, tracks revised MRPs and handles overcharging cases.
• Scheduled and non-scheduled drugs (Economy): This action covers non-scheduled drugs through a margin cap, unlike ceiling prices for scheduled drugs.
• National List of Essential Medicines (Economy): NLEM drugs form the First Schedule of DPCO, which separates scheduled from non-scheduled drugs.
• Maximum Retail Price (Economy): The cap works by lowering the MRP printed on packs, which consumers can check and complain about.
• Out-of-pocket expenditure (Economy): Cancer care causes heavy out-of-pocket spending and borrowing, which is the affordability problem the cap targets.
• Ayushman Bharat PM-JAY (Economy): It covers only inpatient care, so price cuts help with outpatient medicine bills it leaves out.
• Pharma Sahi Daam (Polity): NPPA's app, with the Pharma Jan Samadhan portal, lets consumers verify revised prices and report overcharging.
• Price control (Economy): The wider idea of government regulating prices, of which this margin cap is one form.
• Compulsory licensing (Economy): An alternative route to cheaper cancer drugs that works on patents, not on trade margins.
• Essential commodities (Economy): DPCO is issued under the Essential Commodities Act, which is the source of the government's price powers.

18. Common Errors / Trap Areas

• Wrong ministry: NPPA is not under the Health Ministry, even though DGHS constituted the committee [1].
• 137 vs 121 vs 1,364: 137 drugs were capped, 121 drugs had been reported by 8 November, and 1,364 is a count of formulations [1]. "1,364 drugs" is wrong.
• Scheduled vs non-scheduled: This is a Para 19 action on non-scheduled drugs, not a ceiling price for NLEM drugs [2][9].
• Projected vs reported: "Up to 70%" was the projection and 96.45% is the highest reported cut [1][2].
• Conflicting figures and dates:
• Savings: Use ₹3,540.38 crore, the latest figure tied to reported data [1], not ₹2,500 crore [7].

• Committee date: The digest gives 17 October 2026 as the date the committee was constituted [1]. That is also the Gazette date [2], so it may be a conflation. Check the release before memorising it.

• Standard facts not confirmed by a whitelisted source in this run, so verify them separately:

• NPPA's establishment in 1997.
• DPCO being issued under the Essential Commodities Act, 1955.
• The 10% annual MRP increase limit for non-scheduled drugs.